F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
43 hedge funds and large institutions have $53.2M invested in F-star Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
16% more funds holding
Funds holding: 37 → 43 (+6)
3.78% more ownership
Funds ownership: 47.64% → 51.42% (+3.8%)
17% less call options, than puts
Call options by funds: $151K | Put options by funds: $183K
26% less capital invested
Capital invested by funds: $71.9M → $53.2M (-$18.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.87M |
| 2 |
Renaissance Technologies
New York
|
+$1.03M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$409K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$209K |
| 5 |
Millennium Management
New York
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$12.8M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.82M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.24M |
| 4 |
Janus Henderson Group
London,
|
-$942K |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$20K |
FSTX Hedge Fund Activity: Q4 2021 in Review
43 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q4 2021, worth a combined $53.2M — down 26% from $71.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new FSTX positions and 5 closed out — a net gain of 6 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.87M. The largest seller was Boxer Capital, exiting entirely with an estimated $12.8M sold.
- 43 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q4 2021, up from 37 in Q3 2021.
- Funds reported $53.2M of F-star Therapeutics, Inc. Common Stock stock for Q4 2021, down 26% quarter-over-quarter.
- 11 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q4 2021 and 5 closed out, a net change of +6 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q4 2021 was Anson Funds Management, an estimated $1.87M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q4 2021 was Boxer Capital, an estimated $12.8M sold.
Based on aggregated 13F filings for Q4 2021.